Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Amazon

Wells Fargo

There's something for every type of value investor.

3 of the Biggest Bargains in Buffett's Portfolio

Bausch Health Companies Inc

Dr. Reddy's Labs

3 Generic Drug Stocks to Watch Amid COVID-Induced Uncertainty

Is Teva Pharmaceutical (TEVA) a great pick from the value investor's perspective right now? Read on to know more.

Is Teva Pharmaceutical (TEVA) a Good Stock to Pick Now?

LOS ANGELES--(BUSINESS WIRE)---- $TEVA #TEVA--DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Teva Pharmaceuticals Industries Limited

DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Teva Pharmaceuticals Industries Limited and Encourages Investors with Losses of $100,000 to Contact the Firm

Barrick Gold

Liberty Latin America Ltd.

Liberty Latin America

Sirius XM Holdings Inc

Suncor Energy

Berkshire Hathaway Inc. (NYSE: BRK-A) (NYSE: BRK-B) CEO Warren Buffett is one of the world's richest people, with a net worth of around $86 billion. Unfortunately for small retail investors who want to follow in Buffett's footsteps, buying even one share of Berkshire Hathaway is rather pricey.

5 Warren Buffett Stocks To Buy For Under $25

Los Angeles, California--(Newsfile Corp. - November 20, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Teva Pharmaceuticals Industries Limited (NYSE: TEVA) ("Teva" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between October 29, 2015 and August 18, 2020,...

MONDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Teva Pharmaceuticals Industries Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - November 19, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Teva Pharmaceuticals Industries Limited (NYSE: TEVA) ("Teva" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between October 29, 2015 and August 18,...

MONDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Teva Pharmaceuticals Industries Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 18, 2020) - If you suffered losses exceeding $50,000 investing in Teva stock or options between October 29, 2015 and August 18, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/TEVA or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Teva Shareholder Alert

Los Angeles, California--(Newsfile Corp. - November 18, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Teva Pharmaceuticals Industries Limited ("Teva" or "the Company") (NYSE: TEVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between October 29, 2015 and August 18,...

MONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Teva Pharmaceuticals Industries Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 17, 2020) - If you suffered losses exceeding $50,000 investing in Teva stock or options between October 29, 2015 and August 18, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/TEVA or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Teva Deadline Alert

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 15, 2020) - If you suffered losses exceeding $50,000 investing in Teva stock or options between October 29, 2015 and August 18, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/TEVA or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Teva Lead Plaintiff Deadline Alert

NEW YORK, Nov. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds the purchasers of the securities of Teva Pharmaceuticals Industries Limited (NYSE: TEVA) between October 29, 2015 and August 18, 2020, inclusive (the "Class Period"), of the important...

ROSEN, A LEADING AND RESPECTED LAW FIRM, Reminds Teva Pharmaceuticals Industries Limited Investors of the Important November 23 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $500K to Contact the Firm - TEVA

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 14, 2020) -  If you suffered losses exceeding $50,000 investing in Teva stock or options between October 29, 2015 and August 18, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/TEVA or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Teva Update

Teva's revenues disappointed, but this was likely due to COVID-dependent market volatility. In contrast, margins were up significantly, which should benefit long-term shareholders over time.

Teva Q3 2020 In-Depth Review

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 11, 2020) -  If you suffered losses exceeding $50,000 investing in Teva stock or options between October 29, 2015 and August 18, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/TEVA or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Teva Shareholder Notice

New York, New York--(Newsfile Corp. - November 11, 2020) - Rosen Law Firm, a global investor rights law firm, reminds the purchasers of the securities of Teva Pharmaceuticals Industries Limited (NYSE: TEVA) between October 29, 2015 and August 18, 2020, inclusive (the "Class Period"), of the important November 23, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Teva investors under the federal securities laws.To join the Teva...

Rosen, Leading Trial Attorneys, Reminds Teva Pharmaceuticals Industries Limited Investors of the Important November 23 Deadline in Securities Class Action - TEVA

ATLAS CORP

Boise Cascade

Canadian Solar

Labcorp Holdings Inc

Pampa Energia

When it comes to valuation metrics, though P/E and P/S are the first choices, the P/B ratio is also emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.

6 Low Price-to-Book Value Stocks to Tap Market Boom

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 8, 2020) - If you suffered losses exceeding $50,000 investing in Teva stock or options between October 29, 2015 and August 18, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/TEVA or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Teva Class Action Reminder

New York, New York--(Newsfile Corp. - November 7, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds the purchasers of the securities of Teva Pharmaceuticals Industries Limited (NYSE: TEVA) between October 29, 2015 and August 18, 2020, inclusive (the "Class Period"), of the important November 23, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Teva investors under the federal securities laws.To join the Teva class...

ROSEN, A TOP RANKED FIRM, Reminds Teva Pharmaceuticals Industries Limited Investors of the Important November 23 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $500K to Contact the Firm - TEVA

TEVA's earnings match estimates while sales miss the same for third-quarter 2020. It lowers its previously issued sales guidance for 2020.

TEVA Posts In-Line Q3 Earnings, Lowers Sales View, Stock Down

Teva Pharmaceutical Industries Ltd (TEVA) CEO Kare Schultz on Q3 2020 Results - Earnings Call Transcript

Early Thursday, Teva Pharmaceutical reported adjusted earnings of 58 cents per share on $3.98 billion in sales for its third quarter ended Sept. 30. In response, Teva stock slipped.

Generic Pharma Behemoth Skids As Earnings Stall, Sales Lag Forecasts

TEVA's earnings match estimates while sales miss the same in third-quarter 2020. It maintains its previously issued guidance for 2020.

TEVA Q3 Earnings In Line, Sales Miss, Stock Down

Shares of Teva Pharmaceutical Industries Ltd. gained 0.4% in premarket trading on Thursday after it beat revenue expectations for the third quarter.

Teva's stock gains as it meets earnings expectations for the third quarter

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended September 30, 2020. Mr. Kåre Schultz, Teva's President and CEO, said, “Teva's business and operations have shown resilience as the COVID-19 pandemic continues to impact the world. The quarter saw continued strong performance from our key growth drivers, led by AUSTEDO® and the biosimilar TRUXIMA®, while the market share of AJOVY® continued to grow in the U

News for Teva Pharmaceutical Stock (TEVA)